Therapy From a Novel Substernal Lead

Boersma, Lucas V.A.; Merkely, Béla; Neužil, Petr; Crozier, Ian; Akula, Devender; Timmers, Liesbeth; Kalarus, Zbigniew; Sherfesee, Lou; DeGroot, Paul; Thompson, Amy; Lexcen, Daniel R.; Knight, Bradley P.

doi:10.1016/j.jacep.2018.11.003

Cited by 34 publications

(44 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ASD2 61 was the first human study to evaluate a novel approach to ICD therapy -substernal leads. Pacing threshold, sensing, and defibrillation efficacy were assessed among 79 patients who had undergone lead implantation.…”

Section: Substernal Leadsmentioning

confidence: 99%

See 1 more Smart Citation

<p>Cardiac Electronic Devices: Future Directions and Challenges</p>

Kotalczyk¹,

Kalarus²,

Wright³

et al. 2020

MDER

Self Cite

View full text Add to dashboard Cite

Cardiovascular implantable electronic devices (CIEDs) are essential management options for patients with brady-and tachyarrhythmias or heart failure with concomitant optimal pharmacotherapy. Despite increasing technological advances, there are still gaps in the management of CIED patients, eg, the growing number of lead-and pocket-related longterm complications, including cardiac device-related infective endocarditis, requires the greatest care. Likewise, patients with CIEDs should be monitored remotely as a part of a comprehensive, holistic management approach. In addition, novel technologies used in smartwatches may be a convenient tool for long-term atrial fibrillation (AF) screening, especially in high-risk populations. Early detection of AF may reduce the risk of stroke and other AF-related complications. The objective of this review article was to provide an overview of novel technologies in cardiac rhythm-management devices and future challenges related to CIEDs.

show abstract

Section: Substernal Leadsmentioning

confidence: 99%

“…The lower shock energy (compared with the sICD's 80 J) may be beneficial for battery longevity. 61 Indeed, substernal lead therapy may be feasible, and results are promising. Nevertheless, neither long-term follow-up data nor risk of infection and lead extraction are available.…”

Section: Substernal Leadsmentioning

confidence: 99%

<p>Cardiac Electronic Devices: Future Directions and Challenges</p>

Kotalczyk¹,

Kalarus²,

Wright³

et al. 2020

MDER

Self Cite

View full text Add to dashboard Cite

show abstract

“…After a promising feasibility study, 3 the first patient implant of an EV‐ICD system with a novel S‐shaped retrosternal lead in August 2018 marks the beginning of the ongoing pilot study 59,60 . If the predefined efficacy and safety outcomes of the pilot study will be met, a pivotal trial will be launched later within the next year.…”

Section: Future Perspectivesmentioning

confidence: 99%

State‐of‐the‐art consensus on non‐transvenous implantable cardioverter‐defibrillator therapy

Schukro

Santer

Prenner

et al. 2020

Clinical Cardiology

View full text Add to dashboard Cite

Within the last decade, implantable cardioverter-defibrillator (ICD) systems with nontransvenous leads were developed in order to minimize complications related to the cardiovascular position of transvenous ICD leads. This national expert consensus gives an overview of potential indications for the implantation of non-transvenous ICD systems, and provides specific recommendations for implantation, follow-up, and complication management in patients with subcutaneous ICD. Regarding particular issues like the necessity for shock efficacy testing, or the clinical outcome as compared to transvenous ICD, randomized data are expected in the near future.

show abstract

“…In the future, a unified, single-system, nontransvenous ICD with ATP capability may provide a full range of tachyarrhythmia therapies (both ATP and shock) as well as backup rescue bradycardia pacing. 38 In short, the choice of a full-featured traditional transvenous system for the patient described by Johnston et al 1 is recommended.…”

Section: Dr Gimbel Exploresmentioning

confidence: 99%